Pillar Pharmaceuticals II, L.P.
10% owner at Aceragen, Inc.
- Sold, on record
- $9.7M
- Dollars the filings state
- Form 4 sales
- 5
- Latest Aug 9, 2018
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- Aceragen, Inc.10% owner
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale Aceragen, Inc.UnusualSep 3, 2014 2014
Sold 1.7M shares
Pillar Pharmaceuticals II, L.P., Director, 10% owner
Sold 100% of holdings0 shares leftFirst sale on recordFiling
- 2 Form 4 sale Aceragen, Inc.UnusualMay 1, 2017 +971 days
Sold 450,815 shares at $2.26 ($1M)
Pillar Pharmaceuticals II, L.P., Director, 10% owner
Sold 100% of holdings ($1M position)0 shares leftFirst sale on recordFiling
- 3 Form 4 sale Aceragen, Inc.UnusualDec 15, 2017 +228 days
Sold 2.3M shares at $1.96 ($4.5M)
Pillar Pharmaceuticals II, L.P., 10% owner
Sold 100% of holdings ($4.5M position)0 shares leftFiling
- 4 Form 4 sale Aceragen, Inc.UnusualJul 20, 2018 +217 days
Sold 2.8M shares at $0.86 ($2.4M)
Pillar Pharmaceuticals II, L.P., 10% owner
Sold 100% of holdings ($2.4M position)0 shares leftFiling
- 5 Form 4 sale Aceragen, Inc.UnusualAug 9, 2018 +20 days
Sold 300,000 shares at $5.80 ($1.7M)
Pillar Pharmaceuticals II, L.P., 10% owner
Sold 100% of holdings ($1.7M position)0 shares left0.1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (5)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 9, 2018 | Aug 17, 2018 | Aceragen, Inc. | 10% owner | Form 4 sale | 300,000 | $1.7M | 100.0% | Unusual | SEC |
| Jul 20, 2018 | Jul 24, 2018 | Aceragen, Inc. | 10% owner | Form 4 sale | 2.8M | $2.4M | 100.0% | Unusual | SEC |
| Dec 15, 2017 | Dec 15, 2017 | Aceragen, Inc. | 10% owner | Form 4 sale | 2.3M | $4.5M | 100.0% | Unusual | SEC |
| May 1, 2017 | May 3, 2017 | Aceragen, Inc. | Director, 10% owner | Form 4 sale | 450,815 | $1M | 100.0% | Unusual | SEC |
| Sep 3, 2014 | Sep 4, 2014 | Aceragen, Inc. | Director, 10% owner | Form 4 sale | 1.7M | 100.0% | Unusual | SEC |